PMID- 25714013
OWN - NLM
STAT- MEDLINE
DCOM- 20151214
LR  - 20191028
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 6
IP  - 6
DP  - 2015 Feb 28
TI  - Poor survival is associated with the methylated degree of zinc-finger protein 545 
      (ZNF545) DNA promoter in gastric cancer.
PG  - 4482-95
AB  - Zinc-finger protein 545 (ZNF545) was identified as a gastric tumour suppressor 
      and potentially independent prognostic factor. At the present study, we found 
      that lower expression of ZNF545 was specific in gastric cancer (GC) tissues, and 
      the inconsistently methylated levels of ZNF545 promoter were identified in the 
      gastric cancer tissues. In the methylation-specific PCR (MSP) analysis cohort, we 
      found that GC patients with hypermethylated ZNF545 promoter exhibited 
      significantly shorter median OS than those with unmethylated ZNF545 promoter and 
      those with hypomethylated ZNF545 promoter. In the other cohort, we also 
      demonstrated that GC patients with three or more methylated CpG sites in the 
      ZNF545 promoter were significantly associated with poor survival by using the 
      bisulphite gene sequencing (BGS). The methylated degrees of five CpG sites (-232, 
      -214, -176, -144 and -116) could also provide distinct survival discrimination of 
      patients with GC. These findings indicated that the methylated CpG sites of the 
      ZNF545 promoter could be used for the clinical prediction of the prognosis of GC.
FAU - Deng, Jingyu
AU  - Deng J
AD  - Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City 
      Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Liang, Han
AU  - Liang H
AD  - Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City 
      Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Ying, Guoguang
AU  - Ying G
AD  - Central Laboratory, Tianjin Medical University Cancer Hospital, City Key 
      Laboratory of Tianjin Cancer Center and National Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Dong, Qiuping
AU  - Dong Q
AD  - Central Laboratory, Tianjin Medical University Cancer Hospital, City Key 
      Laboratory of Tianjin Cancer Center and National Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Zhang, Rupeng
AU  - Zhang R
AD  - Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City 
      Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for 
      Cancer, Tianjin, China.
FAU - Yu, Jun
AU  - Yu J
AD  - Institute of Digestive Disease, Li Ka Shing Institute of Health Science, Chinese 
      University of HongKong, Shatin, HongKong.
FAU - Fan, Daiming
AU  - Fan D
AD  - State Key Laboratory of Cancer Biology and Institute of Digestive Diseases, 
      Xijing Hospital, Fourth Military Medical University, Xi'an, China.
FAU - Hao, Xishan
AU  - Hao X
AD  - Department of Gastroenterology, Tianjin Medical University Cancer Hospital, City 
      Key Laboratory of Tianjin Cancer Center and National Clinical Research Center for 
      Cancer, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Nuclear Proteins)
RN  - 0 (ZFP82 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis/*genetics
MH  - Blotting, Western
MH  - Cohort Studies
MH  - CpG Islands/genetics
MH  - DNA Methylation/*genetics
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/*genetics
MH  - Prognosis
MH  - *Promoter Regions, Genetic
MH  - Proportional Hazards Models
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stomach Neoplasms/genetics/mortality/*pathology
PMC - PMC4414205
COIS- Disclosure statement The authors have no conflict of interest.
EDAT- 2015/02/26 06:00
MHDA- 2015/12/15 06:00
PMCR- 2015/02/01
CRDT- 2015/02/26 06:00
PHST- 2014/11/16 00:00 [received]
PHST- 2014/12/11 00:00 [accepted]
PHST- 2015/02/26 06:00 [entrez]
PHST- 2015/02/26 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
PHST- 2015/02/01 00:00 [pmc-release]
AID - 2916 [pii]
AID - 10.18632/oncotarget.2916 [doi]
PST - ppublish
SO  - Oncotarget. 2015 Feb 28;6(6):4482-95. doi: 10.18632/oncotarget.2916.